Records
Every government record, registry entry, journal paper and filing we have checked, in one list. Filter by peptide or type. Each row says what the record says, what we could not confirm, and the day we opened it.
21 records. Filters need JavaScript.
- Investigational Peptides in Orthopaedic Practice: BPC-157, Thymosin Beta-4 and TB-500
Status: Online ahead of print. Narrative review of BPC-157, thymosin beta-4 and TB-500, searched through June 2026. Calls TB-500 a distinct seven-amino-acid fragment often conflated with full-length thymosin beta-4. Finds no FDA-approved musculoskeletal indication, product quality concerns, and concludes routine clinical use cannot currently be recommended.
Caveat: Abstract read; full text not read.
Verified Oct 31, 2026
- BPC-157 pilot after rotator cuff repair (University of Arkansas)
Status: Not yet recruiting. Summary says 20 patients, enrollment field says 30.
Verified Oct 31, 2026
- Fifty 1 Labs Reg A offering (part II and III)
Status: Filed. Biotechnology company focused on peptide products, naming BPC-157 and TB-500.
Verified Oct 31, 2026
- Open-label BPC-157 supplement gummy study (Parlay Wellness)
Status: Completed. 40 participants, 8 weeks, no control group, registered after it ended.
Verified Oct 31, 2026
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats
Status: Published. 32 rats after Achilles tendon repair, 4 weeks. TB-500 group had higher load to failure and better tendon scores than controls; the BPC-157 and TB-500 combination added no benefit over either alone. Authors call it exploratory.
Caveat: Abstract read; full text, funding and disclosures not read.
Verified Oct 31, 2026
- Apparatus and method for peptide stack determination
Status: Published. Applicant: Ageless Medicine Systems. Priority Dec 10, 2024.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- FDA briefing document for July 2026 advisory committee: TB-500 (free base and acetate)
Status: Proposed not to add to 503A list. No human data found. No repeat-dose, genotoxicity or carcinogenicity studies. Poorly characterized. Immunogenicity risk.
Verified Oct 31, 2026
- FDA staff briefing for the committee on BPC-157
Status: Criteria weighed against listing. Only UC use evaluated; sparse human data; animal clotting and liver signals.
Verified Oct 31, 2026
- FDA page: bulk substances that may present significant safety risks (thymosin beta-4 fragment LKKTETQ, TB-500)
Status: Listed. Immunogenicity risk for certain routes; no human exposure data identified. Content current Apr 22, 2026.
Verified Oct 31, 2026
- Simultaneous analysis of food-borne doping substances using liquid ... (a testing method; title shortened)
Status: Published application. Applicant: Korea Institute of Science and Technology. Priority Oct 7, 2024.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Phase 1/2 placebo-controlled TB-500 study in stable ASCVD (Hudson Biotech)
Status: Recruiting. Planned 80 participants, three dose cohorts, one site in Shenzhen. Estimated primary completion Feb 2027. No results posted.
Caveat: Record summary says: This fictional study is an example of a ClinicalTrials.gov-style record. Unverified.
Verified Oct 31, 2026
- Phase 2 placebo-controlled BPC-157 in acute hamstring strain (Hudson Biotech)
Status: Recruiting. Planned 120 participants, Shenzhen, started Feb 2, 2026.
Verified Oct 31, 2026
- Synergistic combination of NAD+ and therapeutic peptides delivered via ... (title shortened by Google Patents)
Status: Published application. Applicant: Nicholas Jerome Andrews. Priority Apr 22, 2024. Second US application in the same family of titles.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Synergistic combination of NAD+ and therapeutic peptides delivered via ... (title shortened by Google Patents)
Status: Published application. Applicant: Nicholas Jerome Andrews. Priority Apr 22, 2024. Matched TB-500 with thymosin.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Regenerative Medical Technology Group 10-Q (BPC-157 and TB-500 pen)
Status: Filed. Describes a BPC-157 and TB-500 injectable pen as current best seller.
Verified Oct 31, 2026
- Composition for tissue regeneration and wound healing containing thymosin beta- ... (title shortened by Google Patents)
Status: Published application. Applicant: Korea Institute of Science and Technology. Priority Dec 19, 2023.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Application of TB500 in the preparation of drugs for preventing or treating ... (title shortened by Google Patents)
Status: Published application. Applicant: Guangdong Ocean University. Priority Aug 30, 2023.
Caveat: Claims and legal status not read.
Verified Oct 31, 2026
- Quantification of TB-500 and its metabolites in vitro and in rats (UHPLC-Orbitrap MS/MS)
Status: Published. Analytical method paper with in-vitro wound-healing screening.
Caveat: Month unknown; Jan 1 is a placeholder. Abstract not read.
Verified Oct 31, 2026
- Warning letter to Warrior Labz naming TB-500 and BPC-157
Status: Issued. Online seller offering TB-500 and BPC-157 alongside SARMs.
Caveat: Found by web search; list may be incomplete.
Verified Oct 31, 2026
- WADA 2022 Prohibited List, S2: Thymosin-beta4 and its derivatives e.g. TB-500
Status: Prohibited
Caveat: Only the 2022 edition was checked.
Verified Oct 31, 2026
- Phase 1 oral BPC-157 tablets in healthy volunteers (PharmaCotherapia)
Status: Status unknown. Planned 42 volunteers in Tijuana; last verified Oct 2015; no results.
Caveat: Month of posting approximate.
Verified Oct 31, 2026
Records are added when we verify them against the primary source. A record here is not an endorsement of what it says. Missing items are listed on each dossier under “Still not covered.”